Xie Yunchang, Li Qinglian, Qin Xiangjing, Ju Jianhua, Ma Junying
CAS Key Laboratory of Tropical Marine Bioresources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, Research Network for Applied Microbiology Center for Marine Microbiology, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China.
College of Earth Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
Metab Eng Commun. 2019 Jan 5;8:e00084. doi: 10.1016/j.mec.2018.e00084. eCollection 2019 Jun.
Three atypical regulatory genes, have been discovered within the himastatin biosynthetic gene cluster (BGC) in ATCC 53653 and the roles of their products have been identified. HmtA and HmtD do not show any structurally distinct features characteristic of regulatory function yet were shown to play important repressive and stimulatory roles, respectively, related to himastatin biosynthesis. HmtB encodes a conserved acetylglutamate kinase; new member of this family serves as repressor of secondary metabolism. Through repressive networks engineering, the limiting functions of HmtA and HmtB along with the activating functions of HmtD in the himastatin BGC have been identified for the first time by gene activation, qPCR, RT-PCR and HPLC studies of selected mutant strains; two of these mutant strains (Δ and Δ) produced himastatin in titers (19.02 ± 1.2 μg/mL, 9.9 folds and 30.40 ± 0.83 μg/mL, 15.8 folds) far exceeding those of the wild-type (WT) producer. Overall, this work provides significant insight into secondary metabolic regulatory mechanisms in . These efforts also highlight and validate a new strategy enabling expanded exploitation of cyclopeptidic natural products such as himastatin that demonstrate exciting antimicrobial and antitumor potentials.
在ATCC 53653的喜他汀生物合成基因簇(BGC)中发现了三个非典型调控基因,并确定了其产物的作用。HmtA和HmtD在结构上未表现出任何调控功能特有的明显特征,但分别被证明在喜他汀生物合成中发挥重要的抑制和刺激作用。HmtB编码一种保守的乙酰谷氨酸激酶;该家族的新成员作为次级代谢的阻遏物。通过阻遏网络工程,首次通过对选定突变株的基因激活、qPCR、RT-PCR和HPLC研究,确定了喜他汀BGC中HmtA和HmtB的限制功能以及HmtD的激活功能;其中两个突变株(Δ和Δ)产生的喜他汀效价(19.02±1.2μg/mL,9.9倍和30.40±0.83μg/mL,15.8倍)远远超过野生型(WT)生产者。总体而言,这项工作为[具体物种名称未给出]的次级代谢调控机制提供了重要见解。这些努力还突出并验证了一种新策略,能够扩大对具有令人兴奋的抗菌和抗肿瘤潜力的环肽类天然产物(如喜他汀)的开发利用。